Proteogenomic analysis dissects early-onset breast cancer patients with prognostic relevance
0
조회
0
다운로드
0
인용
0
참고문헌
초록
Early-onset breast cancer is known for its aggressive clinical characteristics and high prevalence in East Asian countries, but a comprehensive understanding of its molecular features is still lacking. In this study, we conducted a proteogenomic analysis of 126 treatment-naïve primary tumor tissues obtained from Korean patients with young breast cancer (YBC) aged ≤40 years. By integrating genomic, transcriptomic, and proteomic data, we identified five distinct functional subgroups that accurately represented the clinical characteristics and biological behaviors of patients with YBC. Our integrated approach could be used to determine the proteogenomic status of HER2, enhancing its clinical significance and prognostic value. Furthermore, we present a proteome-based homologous recombination deficiency (HRD) analysis that has the potential to overcome the limitations of conventional genomic HRD tests, facilitating the identification of new patient groups requiring targeted HR deficiency treatments. Additionally, we demonstrated that protein–RNA correlations can be used to predict the late recurrence of hormone receptor-positive breast cancer. Within each molecular subtype of breast cancer, we identified functionally significant protein groups whose differential abundance was closely correlated with the clinical progression of breast cancer. Furthermore, we derived a recurrence predictive index capable of predicting late recurrence, specifically in luminal subtypes, which plays a crucial role in guiding decisions on treatment durations for YBC patients. These findings improve the stratification and clinical implications for patients with YBC by contributing to the optimal adjuvant treatment and duration for favorable clinical outcomes.
Abstract
Early-onset breast cancer is known for its aggressive clinical characteristics and high prevalence in East Asian countries, but a comprehensive understanding of its molecular features is still lacking. In this study, we conducted a proteogenomic analysis of 126 treatment-naïve primary tumor tissues obtained from Korean patients with young breast cancer (YBC) aged ≤40 years. By integrating genomic, transcriptomic, and proteomic data, we identified five distinct functional subgroups that accurately represented the clinical characteristics and biological behaviors of patients with YBC. Our integrated approach could be used to determine the proteogenomic status of HER2, enhancing its clinical significance and prognostic value. Furthermore, we present a proteome-based homologous recombination deficiency (HRD) analysis that has the potential to overcome the limitations of conventional genomic HRD tests, facilitating the identification of new patient groups requiring targeted HR deficiency treatments. Additionally, we demonstrated that protein–RNA correlations can be used to predict the late recurrence of hormone receptor-positive breast cancer. Within each molecular subtype of breast cancer, we identified functionally significant protein groups whose differential abundance was closely correlated with the clinical progression of breast cancer. Furthermore, we derived a recurrence predictive index capable of predicting late recurrence, specifically in luminal subtypes, which plays a crucial role in guiding decisions on treatment durations for YBC patients. These findings improve the stratification and clinical implications for patients with YBC by contributing to the optimal adjuvant treatment and duration for favorable clinical outcomes.
참고문헌 (75)
- Hong, S., "Cancer Statistics in Korea : Incidence, mortality, survival, and pre valence in 2017", Cancer Res Treat, 52, pp.335~350 (2020)
- Sung, H., "Global Cancer Statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J. Clin, 71, pp.209~249 (2021)
- Kang, S. Y., "Breast Cancer Statistics in Korea, 2018", J. Breast Cancer, 24, pp.123~137 (2021)
- DeSantis, C. E., "Breast cancer statistics, 2019", CA Cancer J. Clin, 69, pp.438~451 (2019)
- Ahn, S. H., "Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance : nationwide survival data in Korea-a report from the Korean Breast Cancer Society", J. Clin. Oncol, 25, pp.2360~2368 (2007)
- Azim, H. A. Jr, "Biology of breast cancer in young women", Breast Cancer Res, 16, pp.427~ (2014)
- Partridge, A. H., "Subtype-dependent relationship between young age at diagnosis and breast cancer survival", J. Clin. Oncol, 34, pp.3308~3314 (2016)
- Kim, J., "Analysis of the tumor characteristics in young age breast cancer patients using collaborative stage data of the Korea Central Cancer Registry", Breast Cancer Res. Treat, 187, pp.785~792 (2021)
- Liao, S., "The molecular landscape of premenopausal breast cancer", Breast Cancer Res, 17, pp.104~ (2015)
- Kan, Z., "Multi-omics profiling of younger Asian breast cancers reveals dis tinctive molecular signatures", Nat. Commun, 9, pp.1725~ (2018)
- Colak, D., "Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women", PLoS One, 8, pp.e63204~ (2013)
- Mertins, P., "Proteogenomics connects somatic mutations to signalling in breast cancer", Nature, 534, pp.55~62 (2016)
- Johansson, H. J., "Breast cancer quantitative proteome and proteogenomic landscape", Nat. Commun, 10, pp.1600~ (2019)
- Krug, K., "Proteogenomic landscape of breast cancer tumorigenesis and targeted therapy", Cell, 183, pp.1436~1456 (2020)
- Li, H., "Fast and accurate short read alignment with Burrows-Wheeler transform", Bioinformatics, 25, pp.1754~1760 (2009)
- DePristo, M. A., "A framework for variation discovery and genotyping using next-generation DNA sequencing data", Nat. Genet, 43, pp.491~498 (2011)
- McKenna, A., "The genome analysis Toolkit : a MapReduce framework for analyzing next-generation DNA sequencing data", Genome Res, 20, pp.1297~1303 (2010)
- Cibulskis, K., "Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples", Nat. Biotechnol, 31, pp.213~219 (2013)
- Ramos, A. H., "Oncotator : cancer variant annotation tool", Hum. Mutat, 36, pp.E2423~E2429 (2015)
- Kanchi, K. L., "Integrated analysis of germline and somatic variants in ovarian cancer", Nat. Commun, 5, pp.3156~ (2014)
- Zanti, M., "Performance evaluation of pipelines for mapping, variant calling and interval padding, for the analysis of NGS germline panels", BMC Bioinforma, 22, pp.218~ (2021)
- "FastQC (v0.11.7)" (2010)[URL]
- "Trim Galore"[URL]
- Mertins, P., "Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry", Nat. Protoc, 13, pp.1632~1661 (2018)
- Wang, Y., "Reversed-phase chromatography with multiple fraction con catenation strategy for proteome profiling of human MCF10A cells", Proteomics, 11, pp.2019~2026 (2011)
- Mun, D. G., "Proteogenomic characterization of human early-onset gastric cancer", Cancer Cell, 35, pp.111~124 (2019)
- Favero, F., "Sequenza : allele-specific copy number and mutation profiles from tumor sequencing data", Ann. Oncol, 26, pp.64~70 (2015)
- Sztupinszki, Z., "Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer", NPJ Breast Cancer, 4, pp.16~ (2018)
- Zhao, E. Y., "Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer", Clin. Cancer Res, 23, pp.7521~7530 (2017)
- Robinson, M. D., "edgeR : a Bioconductor package for differential expression analysis of digital gene expression data", Bioinformatics, 26, pp.139~140 (2010)
- Trapnell, C., "Differential analysis of gene regulation at transcript resolution with RNA-seq", Nat. Biotechnol, 31, pp.46~53 (2013)
- Love, M. I., "Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2", Genome Biol, 15, pp.550~ (2014)
- Lawrence, M. S., "Mutational heterogeneity in cancer and the search for new cancer-associated genes", Nature, 499, pp.214~218 (2013)
- Gendoo, D. M., "Genefu : an R", Bioconductor package for computation of gene expression-based signatures in breast cancer, 2016, pp.32, 1097~1099
- Liberzon, A., "The Molecular Signatures Database (MSigDB) hallmark gene set collection", Cell Syst, 1, pp.417~425 (2015)
- Reich, M., "GenePattern 2.0", Nat. Genet, 38, pp.500~501 (2006)
- Yoshihara, K., "Inferring tumour purity and stromal and immune cell admixture from expression data", Nat. Commun, 4, pp.2612~ (2013)
- Newman, A. M., "Robust enumeration of cell subsets from tissue expression profiles", Nat. Methods, 12, pp.453~457 (2015)
- Aran, D., "xCell : digitally portraying the tissue cellular het erogeneity landscape", Genome Biol, 18, pp.220~ (2017)
- Becht, E., "Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression", Genome Biol, 17, pp.218~ (2016)
- Angelova, M., "Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel tar gets for immunotherapy", Genome Biol, 16, pp.64~ (2015)
- Thorsson, V., "The immune landscape of cancer", Immunity, 51, pp.411~412 (2019)
- Blumenberg, L., "BlackSheep: A bioconductor and bioconda package for differential extreme value analysis", J. Proteome Res, 20, pp.3767~3773 (2021)
- Wiredja, D. D., "The KSEA App : a web-based tool for kinase activity inference from quantitative phosphoproteomics", Bioinformatics, 33, pp.3489~3491 (2017)
- Hornbeck, P. V., "PhosphoSitePlus : a comprehensive resource for investi gating the structure and function of experimentally determined post translational modifications in man and mouse", Nucleic Acids Res, 40, pp.D261~D270 (2012)
- Linding, R., "NetworKIN : a resource for exploring cellular phosphorylation networks", Nucleic Acids Res, 36, pp.D695~D699 (2008)
- Guiu, S., "Molecular subclasses of breast cancer : how do we define them? The IMPAKT 2012 Working Group Statement", Ann. Oncol, 23, pp.2997~3006 (2012)
- Pan, J. W., "The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences", Nat. Commun, 11, pp.6433~ (2020)
- Encinas, G., "Somatic mutations in early onset luminal breast cancer", Onco target, 9, pp.22460~22479 (2018)
- Stephens, P. J., "The landscape of cancer genes and mutational processes in breast cancer", Nature, 486, pp.400~404 (2012)
- Pereira, B., "The somatic mutation profiles of 2, 433 breast cancers refines their genomic and transcriptomic landscapes", Nat. Commun, 7, pp.11479~ (2016)
- Ellis, M. J., "Whole-genome analysis informs breast cancer response to aro matase inhibition", Nature, 486, pp.353~360 (2012)
- Kaufmann, M., "Long-term risk of breast cancer recurrence : the need for extended adjuvant therapy", J. Cancer Res. Clin. Oncol, 131, pp.487~494 (2005)
- Katz, E., "A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk", Br. J. Cancer, 103, pp.401~410 (2010)
- Bai, T., "GRB-7 facilitates HER-2", Neu-mediated signal transduction and tumor formation, 2008, pp.29, 473~479
- Wolff, A. C., "Human epidermal growth factor Receptor 2 testing in breast cancer : American Society of Clinical Oncology", College of American Pathologists Clinical Practice Guideline Focused Update, 2018, pp.36, 2105~2122
- Landrum, M. J., "ClinVar : public archive of interpretations of clinically relevant variants", Nucleic Acids Res, 44, pp.D862~D868 (2016)
- Shiovitz, S., "Genetics of breast cancer : a topic in evolution", Ann. Oncol, 26, pp.1291~1299 (2015)
- Lin, C. H., "Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population", J. Natl Cancer Inst, 111, pp.1298~1306 (2019)
- Johansson, A. L. V., "Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort", Int J. Cancer, 144, pp.1251~1261 (2019)
- Anders, C. K., "Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression", J. Clin. Oncol, 26, pp.3324~3330 (2008)
- Azim, H. A. Jr, "Genomic aberra tions in young and elderly breast cancer patients", BMC Med, 13, pp.266~ (2015)
- Perou, C. M., "Molecular portraits of human breast tumours", Nature, 406, pp.747~752 (2000)
- Nielsen, T. O., "A comparison of PAM50 intrinsic subtyping with immuno histochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer", Clin. Cancer Res, 16, pp.5222~5232 (2010)
- Liu, M. C., "PAM50 gene signatures and breast cancer prognosis with adju vant anthracycline-and taxane-based chemotherapy : correlative analysis of C9741(Alliance)", NPJ Breast Cancer, 2, pp.15023~ (2016)
- Telli, M. L., "Asian ethnicity and breast cancer subtypes : a study from the California Cancer Registry", Breast Cancer Res Treat, 127, pp.471~478 (2011)
- Allard, B., "Immuno-oncology-101 : overview of major concepts and transla tional perspectives", Semin Cancer Biol, 52, pp.1~11 (2018)
- Gajewski, T. F., "The next hurdle in cancer immunotherapy : overcoming the non-T cell-inflamed tumor microenvironment", Semin Oncol, 42, pp.663~671 (2015)
- Savas, P., "Clinical relevance of host immunity in breast cancer : from TILs to the clinic", Nat. Rev. Clin. Oncol, 13, pp.228~241 (2016)
- Alexandrov, L. B., "Signatures of mutational processes in human cancer", Nature, 500, pp.415~421 (2013)
- Emens, L. A., "Breast cancer immunotherapy : facts and hopes", Clin. Cancer Res, 24, pp.511~520 (2018)
- Adams, S., "Current landscape of immunotherapy in breast cancer : a review", JAMA Oncol, 5, pp.1205~1214 (2019)
- Karn, T., "Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo", Ann. Oncol, 31, pp.1216~1222 (2020)
- Yao, J., "Identification of breast cancer immune subtypes by analyzing bulk tumor and single cell transcriptomes", Front Cell Dev. Biol, 9, pp.781848~ (2021)